NewsRoom Articles - Page 111 of 154 - PsychedelicNewsWire (PNW)

MondayDec 28, 2020 3:30 pm

New Research Discovers Connection Between Psychedelic Experiences, Personality Traits

Psychedelic drugs such as LSD and psilocybin mushrooms are known to cause various effects on different people; those effects range from encounters with entities from out of this world to complete dissolution from the ego. The unique nature of these experiences makes it rather hard for researchers to make definite conclusions concerning the end results of indulging in these psychedelic substances. However, new research shows that there may be a way to forecast how an individual will respond to psychedelics based on a person’s personality. Psychiatrists originally discovered a link between psychedelic drug-related experiences and an individual’s personality structure in…

WednesdayDec 23, 2020 3:00 pm

Researchers Develop Synthetic Ibogaine to Treat Depression, Addiction

Ibogaine is a psychoactive substance that triggers hallucinations; the substance is found in the Apocynaceae family of plants. Ibogaine has been used in spiritual ceremonies by the Bwiti tribe of Gabon for centuries. However, it wasn’t until the ’50s that ibogaine became popular in the West as a treatment for depression and addiction. Despite this rising popularity, however, ibogaine isn’t a medicine per se as it may lead to heart attacks and it’s illegal in most countries. Still, it was used by researchers recently to develop a non-hallucinogenic, non-toxic chemical cousin that helps tackle addictive and depressive behaviors in rodents.…

WednesdayDec 23, 2020 12:53 pm

Pure Extracts Technologies (CSE: PULL) Signs LOI with PURICA(TM) to Further Research into Mushrooms Wellness Products

Pure Extracts Technologies revealed it had recently retained global consultancy to advise on application for Dealer’s License under Health Canada If granted, license would allow Company to cultivate, conduct research into, commercialize controlled substances Pure Extracts also announced it recently signed LOI to further cooperation with PURICA(TM)( in field of full-spectrum mushroom-derived wellness products and co-develop CBD, mushroom product combinations Partnership would ideally situate Company to benefit from growing consumer interest within functional mushroom - CBD oil wellness product segments Pure Extracts Technologies (CSE: PULL) (XFRA: A2QJAJ), a plant-based extraction company, recently revealed that it had begun the process towards…

TuesdayDec 22, 2020 3:15 pm

Psychedelic Company Carrying Out Trials for Coronavirus Treatment

The announcement of the coronavirus vaccines from Pfizer, Moderna and Oxford is a hopeful sign for many. Nonetheless, there’s still a lot that we do not know about the coronavirus infection. However, researchers continue to work diligently to learn more about the SARS-CoV-2 virus, which causes the infection. While the vaccines that have been made are not 100% effective, they are effective enough to help achieve herd immunity, which will assist in efforts to contain the virus that is spreading rapidly, overwhelming health-care facilities and killing without mercy. Many private firms are looking into coronavirus treatments, including Revive Therapeutics (CSE:…

MondayDec 21, 2020 11:00 am

Pure Extracts Technologies Corp. (CSE: PULL) Names Key Advisor; Targets Development of Mushroom Formulations

Pure Extracts is working with Dr. Alexander MacGregor on development of mushroom products, including some combined with CBD. MacGregor is widely renowned as pharmaceutical science inventor, expert in pharmaceutical technology and novel drug-delivery systems. Pure Extracts is focused on expansion of its cannabis extraction business model to include mushroom formulations. Pure Extracts Technologies (CSE: PULL) has established a key collaborative relationship with an expert in translating pharmaceutical knowledge into a sustainable business. The plant-based extraction company, which is focused on cannabis, hemp and the rapidly emerging functional mushroom sector, is working closely with Dr. Alexander MacGregor on developing quality cannabis…

MondayDec 21, 2020 10:00 am

UK Government Expects Huge Return From Psychedelic Investment

Angel CoFund, an investor backed by the UK government, holds a 5.5% stake in Small Pharma, a London-based neuropharmaceutical company. Small Pharma recently announced that it planned to list the firm on the Toronto Stock Exchange through Unilock Capital Corp, a Canadian capital pool, via reverse takeover. The company’s objective is to raise $ 15.6 million, an equivalent of C$20 million, which will finance the clinical trial of dimethyltryptamine/DMT-assisted therapy treatment for depression. DMT is an active compound found in ayahuasca, an Amazonian psychedelic brew. While Angel CoFund is a privately run organization, it is funded by a £100 million…

FridayDec 18, 2020 4:00 pm

How Retired Pro Athletes Use Psychedelics

Former UFC fighters Dean Lister and Ian McCall, former NHL player Daniel Carcillo and former NFL player Kerry Rhodes are a few well-known athletes who current using plant medicines such as psilocybin mushrooms and ayahuasca to help manage brain trauma symptoms and heal their PTSD. Carcillo suffered from mental and physical trauma following the effects of repeated concussions after retiring from the NHL. It wouldn’t have been easy to spot though, given that from the outside, he seemed to have it all — from a successful career to a comfortable home and a lovely family. CTE, or chronic traumatic encephalopathy,…

ThursdayDec 17, 2020 1:50 pm

Pure Extract Technologies (CSE: PULL) Provides Update on Expansion into Functional Mushrooms Sector

Pure Extracts Technologies recently provided update into its expansion into functional mushrooms sector Functional mushrooms have enjoyed surge in popularity as of late, are increasingly being used in wide variety of healthcare, pharmaceutical products Functional mushrooms sector is expected to grow to annual market value of $34.4 billion by 2024 Pure Extracts plans to develop high bio-available products derived from functional mushrooms through use of its proprietary extraction processes Company also set to launch its own branded functional mushrooms-based products under ‘Pure Mushrooms’ brand from Q1 2021 onwards and has signed a LOI with the PURICA(TM) brand of mushroom wellness…

ThursdayDec 17, 2020 1:30 pm

Functional vs. Psilocybin Mushrooms: A Guide to Investing

As psychedelics move into mainstream media, the attention on substances such as psilocybin and MDMA grows. Chances are good that you’ve heard of psilocybin mushrooms, but did you know that an entirely different category of mushrooms exists, nonpsychedelics that are called functional mushrooms. Examples of these mushrooms include reishi, chaga and lion’s mane. These two growing markets can both be considered as potential investment opportunities. Below, we look at their differences and examine the potential for growth and profit for investors. Wellness space or media spotlight: Which is better? Magic mushrooms are hallucinogenic mushrooms that have the psychoactive component psilocybin.…

WednesdayDec 16, 2020 3:00 pm

Canadian Government to Allow Therapists to Use Psilocybin Mushrooms

Canada’s Health Minister Patter Hajdu recently stated that the country would allow some health-care professionals to both consume and possess psilocybin mushrooms. The aim of this move is to provide a way that health-care professionals can better understand and recognize how to treat the increasing number of patients who have been allowed to use the psychedelic. This is the health ministry’s first public response to the psilocybin-use pending applications by therapists. Over the summer, the health ministry allowed a limited number of patients to use psilocybin mushrooms as part of their psychotherapy in their end-of-life care. However, ministry of health…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000